IPO Boutique

uniQure B.V. IPO Advisory

Share this IPO Profile:

Smart Search
Company begins with...
Company contains...

For IPO Boutique's "scale of 1 to 5" BUY rating on uniQure B.V., and our comprehensive analysis, click "Buy Market Research".
Company
Symbol
Price Range
Issue Price
Open
Shares
Trade Date
uniQure B.V.QURE -
NASDAQ
$13.00-$15.00 $17.00 $17.005.4 million2/5/2014
Jefferies, Leerink Swann, Piper Jaffray
Co-Manager(s):
Health Care
Filing(s):

Filed 2014-01-02



uniQure B.V. Quote & Chart - Click for current quote - QURE

About uniQure B.V. (adapted from uniQure B.V. prospectus):
They are a leader in the field of gene therapy and have developed the first and currently the only gene therapy product to receive regulatory approval in the European Union.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.



IPO Boutique aggregates information on public companies and private companies, such as "QURE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.

Used our Comprehensive Single Promo Advisory and want more?
We also offer a monthly or annual subscription






© 2005 - 2024 IPO Boutique. All Rights Reserved